Multi-omics analysis reveals gut microbiota remodeling and lipid metabolism regulation during the treatment of nonalcoholic fatty liver disease with Yindan Pinggan capsule - PubMed
4 hours ago
- #NAFLD
- #Lipid metabolism
- #Gut microbiota
- Yindan Pinggan capsule (YDPG) shows potential in treating nonalcoholic fatty liver disease (NAFLD).
- YDPG reduces body weight, liver inflammation, and improves lipid profiles in a high-fat diet-induced NAFLD mouse model.
- Multi-omics analysis reveals YDPG remodels gut microbiota, decreasing harmful genera and enriching beneficial ones.
- YDPG regulates key metabolites like bile acids, short-chain fatty acids, and neurotransmitters.
- Liver transcriptome profiling shows YDPG acts via PPAR signaling and primary bile acid biosynthesis pathways.
- Key genes (Pparg, Scd1, Cyp7a1, Cyp39a1) involved in these pathways are modulated by YDPG.
- YDPG demonstrates potential as a multi-target therapeutic agent for NAFLD by restoring gut microbial balance and correcting metabolic disorders.